Receiving a diagnosis of endometrial cancer can be a deeply unsettling experience. For many women, the journey begins with the anxiety of unexpected bleeding or pelvic pain, followed by a whirlwind of medical appointments and tests. This diagnosis impacts not only physical health but also emotional well-being and future plans. While the news is serious, it is important to know that endometrial cancer is frequently detected early, making it highly treatable for many women. 

Treatment is vital to remove the cancer, prevent it from spreading to other organs, and manage potential symptoms. Because this cancer develops in the lining of the uterus, treatment plans depend heavily on the stage of the disease, the specific type of cells involved, and a woman’s overall health. Treatment needs vary significantly; while some patients may only require a surgical procedure, others will benefit from a combination of therapies to ensure the best outcome (American Cancer Society, 2023). 

Overview of treatment options for Endometrial Cancer 

The primary treatment for endometrial cancer is almost always surgery to remove the uterus (hysterectomy), usually along with the fallopian tubes and ovaries. For many women with early-stage disease, surgery alone is curative. However, medication-based treatments—known as systemic therapies, play a crucial role when the cancer has spread, is at high risk of returning, or cannot be completely removed surgically. 

The main goals of medication are to destroy remaining cancer cells after surgery (adjuvant therapy), shrink tumors to relieve symptoms, or control the disease in advanced stages. Doctors may use chemotherapy, hormone therapy, immunotherapy, or targeted therapy. The choice depends largely on whether the cancer cells have specific receptors or genetic markers (National Cancer Institute, 2023). 

Medications used for Endometrial Cancer 

Chemotherapy is the standard drug treatment for cancer that has spread beyond the uterus or is considered aggressive. The most common regimen involves a combination of two drugs: carboplatin and paclitaxel. Clinical experience suggests that using these two drugs together is often more effective and better tolerated than older regimens. These are typically given intravenously in cycles. 

Hormone Therapy is frequently used for advanced endometrial cancer or for women who wish to preserve fertility. Since many endometrial tumors grow in response to estrogen, doctors prescribe progestins (synthetic progesterone) to counteract this. Common examples include megestrol acetate and medroxyprogesterone. Alternatively, drugs like tamoxifen may be used. 

Immunotherapy has become a vital option for specific genetic types of endometrial cancer. Drugs like pembrolizumab and dostarlimab are checkpoint inhibitors used for cancers that have a specific genetic feature known as mismatch repair deficiency (dMMR). 

Targeted Therapy focuses on specific weaknesses in cancer cells. Lenvatinib is a drug often prescribed in combination with immunotherapy (pembrolizumab) for patients whose cancer does not have the dMMR marker (Mayo Clinic, 2023). 

How these medications work 

Chemotherapy drugs target rapidly dividing cells throughout the body, damaging their internal structure, preventing replication, and causing cell death. 

Hormone therapy changes the body’s hormonal environment. Progestins slow endometrial cancer growth by blocking estrogen’s effects, essentially “starving” the tumor. 

Immunotherapy “unmasks” cancer cells that normally hide from the immune system. Drugs like pembrolizumab block the disguising proteins, allowing the immune system to recognize and attack the tumor. Targeted therapies like lenvatinib block signals that tell cancer cells to create new blood vessels, limiting the tumor’s blood supply. 

Side effects and safety considerations 

Chemotherapy commonly causes fatigue, hair loss, nausea, and increased infection risk due to low blood cell counts. Hormone therapy is milder, potentially causing weight gain, fluid retention, and hot flashes.  

Immunotherapy can trigger the immune system to attack healthy organs, causing inflammation in the lungs, colon, or thyroid. Targeted therapies may lead to high blood pressure or fatigue. Regular blood tests are necessary to monitor liver and kidney function. Patients must seek immediate care for high fever, severe abdominal pain, or difficulty breathing (American Society of Clinical Oncology, 2022). 

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care. 

References 

  1. American Cancer Society. https://www.cancer.org 
  1. National Cancer Institute. https://www.cancer.gov 
  1. Mayo Clinic. https://www.mayoclinic.org 
  1. American Society of Clinical Oncology. https://www.cancer.net 

Medications for Endometrial Cancer

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Endometrial Cancer.

Found 3 Approved Drugs for Endometrial Cancer

Pembrolizumab

Brand Names
Keytruda QLEX, Keytruda

Pembrolizumab

Brand Names
Keytruda QLEX, Keytruda
KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or metastatic melanoma.

Jemperli

Generic Name
Dostarlimab

Jemperli

Generic Name
Dostarlimab
JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Endometrial Cancer in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC).

Citrtae

Brand Names
MiloPhene, Clomid

Citrtae

Brand Names
MiloPhene, Clomid
Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome, amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS.) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below: 1. Patients who are not pregnant. 2. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. 3. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. 4. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: 1. Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. 2. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. 3. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. 4. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. 5. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses.
Showing 1-3 of 3
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances